Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

Summary

Aurinia announced the initiation of the PRESERVE study investigating the combination of LUPKYNIS with belimumab, obinutuzumab, or anifrolumab in patients with lupus nephritis. This represents a routine trial start announcement with potential for future data generation.